Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients

Inclusion Criteria: * Male or female aged 18 or over 18 years who had no history of antimuscarinic treatment or stopped antimuscarinics at least 3 months prior to the screening visit * Verified by 3-day bladder diary as below * Urgency episode of 2 or over 2 times/24 hours (defined as a level of 3 to 5 in a 5 point urgency scale at baseline) * Urinary frequency of 8 or over 8 times/24 hours * Symptom duration of 3 or over 3 months. * Ability and willingness to correctly complete the micturition diary and questionnaire * Capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits Exclusion Criteria: * Clinically significant stress incontinence as determined by the investigators and confirmed for female patients by a cough provocation test. * Significant hepatic or renal disease, defined as having twice the upper limit of the reference ranges for serum concentrations of aspartate aminotransferase (AST \[SGOT\]), alanine aminotransferase (ALT \[SGPT\]), alkaline phosphatase or creatinine * Any condition that is a contraindication for anticholinergic treatment, including uncontrolled narrow-angled glaucoma, urinary retention or gastric retention * Symptomatic acute urinary tract infection (UTI) during the run-in period * Recurrent UTIs defined as having been treated for symptomatic UTIs \> 4 times in the last year * Diagnosed or suspected interstitial cystitis * Uninvestigated hematuria or hematuria secondary to malignant disease. * Clinically significant bladder outlet obstruction defined by clinical symptoms and investigator's opinion according to local standard of care * Patients with marked cystocele or other clinically significant pelvic prolapse. * Treatment within the 14 days preceding randomization, or expected to initiate treatment during the study with: * Any anticholinergic drugs other than randomized trial drug * Any drug treatment for overactive bladder. Estrogen treatment started more than 2 months prior to inclusion is allowed. * On an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study * Receipt of any electrostimulation or bladder training within the 14 days before randomization, or expected to start such treatment during the study * An indwelling catheter or practicing intermittent self-catheterization * Use of any investigational drug within 2 months preceding the start of the study * Patients with chronic constipation or history of severe constipation * Pregnant or nursing women * Sexually active females of childbearing potential not using reliable contraception for at least 1 month prior to study start and not agreeing to use such methods during the entire study period and for at least 1 month thereafter. Reliable contraceptive methods are defined as intrauterine devices (IUDs), combination type contraceptive pills, hormonal implants, double barrier method, injectable contraceptives and surgical procedures (tubal ligation or vasectomy). * Patients who have bladder cancer or prostate cancer * Treatment with potent CYP3A4 inhibitors, such as cyclosporine, vinblastine, macrolide antibiotics (e.g. erythromycin, clarithromycin, azithromycin) or antifungal agents (e.g. ketoconazole, itraconazole, micronazole). * Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion